Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Forgot to mention another day with more Buys than Sells
Buys = 6.5 million shares
Sells = 5.4 million shares
There was some serious intellect involved in the Canine Vagus Nerve Osteoarthritis Study
Richard Staelin PhD
Professor Duke University
Professor Carnegie Mellon University
Ken McLeod
PhD Electrical Engineering
CEO Sonostics Inc.
Tayna Ella Sprunks
BSc Veterinarian Physiotherapist
Sree Koneru PhD
Director Project Development , Viant Medical
Julie Edell PhD
Carnegie Mellon University
https://europepmc.org/article/MED/38516818
LOL, the BID and or Ask Sizes can be packed with Phantom MM Shares that will disappear in milliseconds if the market sentiment changes direction.
One of the many MM tools used to influence Trading.
The Japanese version of today's PR cut out part of the full PR, below is the full AP PR minus Safe Harbor statement
BioElectronics Corporation Announces Utility Patent Application Filing
FREDERICK, MD - ( NewMediaWire ) - May 21, 2024 - BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the filing of a new USPTO utility patent application addressing the treatment of chronic inflammation. This patent application, numbered 18/667,971, was a collaborative effort of John Martinez, Kenneth McLeod, PhD, and Richard Staelin, PhD. It outlines methods, systems, apparatuses, and devices that modify the immune response through non-invasive stimulation of the vagal nerves. The application draws from the results of a recently completed double-blind, placebo-controlled, canine study, published in Veterinary Medicine and Science which demonstrated that Pulsed Short Wave Therapy (PSWT) Technology applied to the vagal nerves of dogs diagnosed with osteoarthritis resulted in significant reductions in systemic discomfort.
Chronic inflammation poses a significant challenge to modern medicine. While few effective interventions exist, management of the condition often involves removing inflammatory triggers through dietary or lifestyle changes. Additionally, anti-inflammatory medications are commonly used, but their chronic use is costly and associated with significant side effects.
A promising approach for addressing chronic inflammation emerged with the discovery of the inflammatory reflex. Similar to reflexes in the somatic nervous system, this reflex involves both the afferent (incoming) and efferent (outgoing) arms of the vagus nerve. Although vagus nerve stimulation has been shown to suppress pro-inflammatory cytokine levels in the periphery, traditional stimulation techniques are not suitable for chronic vagus nerve stimulation.
BioElectronics’ PSWT technology and device designs overcome this limitation, providing a convenient, economical, and highly effective alternative for treating chronic inflammation. Given that over one-third of Americans suffer from chronic, systemic inflammation, this development opens an enormous new market opportunity for BioElectronics. The company plans to continue its efforts to provide clinical support and develop new designs for its product line.
Nice little EOD Rally, 10.7 Million buys in final 2 hours
The Buy/Sell ratio is the real story today.
Buys = 12.262 million shares
Sells = 4,700 shares (4,500 of those were at .00014)
Neutral = 4.096 million shares (.00015 SP)
That's one opinion, but not necessarily the correct one
The canine osteoarthritis study was published 2 months ago and BIEL likely had data from the results long before it was published.
Plenty of time to present the Study's impressive results to potential partners willing to invest in Vagus Nerve research. I don't see BIEL spending money on new patents unless there is a high probability of a near term benefit.
Patent applications are dated so BIEL's May 2024 application would have priority over any similar applications submitted at a later date.
If Clinicals are needed the duration of the Dog Study data collection, with just 14 days of therapy, was quite short. Since BIEL is now a know entity at the FDA, Cleared for 5 indications, the days of year long Clearance times are over. The Post-surgical Pain Clearance took 4 and a half months from submission to decision.
Yep GG, the Vagus Nerve is packed with more than 100,000 fibers carrying signals from your brain to your body, regulating:
* Heart rate
* Taste
* Speech
* Skin sensations
* Muscle sensations
* Immune response
* Respiratory rate
* Blood pressure
* Mucus production
* Saliva production
* Digestion
* Frequency of urination
* Mood
Its position, running along the side of the neck near the skin surface, allows ActiPatch and RecoveryRx to stimulate it with a pulsed radio frequency magnetic field at 27.1 MHz. The potential is there to help scores of medical conditions from this one neck access point.
Also notice this statement from yesterday's BIEL Facebook posting in reference to the patent application which sounds like much more than just a device patent,
"It outlines methods, systems, apparatuses, and devices that modify the immune response through non-invasive stimulation of the vagal nerves."
The Study which is referenced in today's PR, "Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics", had amazing results,
"Ninety-six per cent of the treatment group showed either increased PROM (passive range of motion) or improved behavioural changes or both, compared to 4% for the placebo group (p < 0.01). Most changes occurred within the first 8 days of treatment."
In the average Study 51% efficacy is considered a good outcome.
https://onlinelibrary.wiley.com/doi/10.1002/vms3.1408
Two options, Frightened Basher BS or Conniving Flipper BS
GetSeriousOK
Re: myjog post# 15609
Thursday, May 09, 2024 2:12:11 PM
Post# 15610
I just bought some today.
Keep bashing and drive it down, and I'll keep buying.
GetSeriousOK
Re: gimmee greenbacks post# 329160
Friday, May 10, 2024 9:36:06 AM
Post# 329170
Yes, SOME enthusiastic shareholders are a laughing matter.
At least there's something to laugh about.
Meanwhile, the MM's keep throwing me scraps at .0001. I never thought the MM's would allow anyone to buy at .0001 -- I thought they were keeping all the .0001's for themselves. My god. Soon I might own more of this crap than you.
Inflammation is currently a hot topic among researchers
Inflammation is the body’s natural defense against injury and infection. Chronic inflammation happens when the body’s inflammatory response activates—sometimes even without injury or illness—and persists over months or years.1 When chronic inflammation persists, it can cause severe damage to the body, leading to long-term health problems such as heart disease, cancer, autoimmune disease, or diabetes.
Chronic, low-grade inflammation can damage healthy cells, tissues, organs, and DNA. Over time, it can weaken your immune system and lead to health problems, including autoimmune and inflammatory diseases. Many conditions are linked to chronic inflammation, including:
Cardiovascular disease: Chronic inflammation can damage blood vessels, causing them to narrow or thicken, increasing the risk of heart disease, stroke, and other cardiovascular problems.
Cancer: Chronic inflammation can damage the DNA in healthy cells, causing them to mutate (change) into abnormal cells. Cancer develops when these abnormal cells grow and multiply uncontrollably. Research suggests chronic inflammation contributes to 15 to 20% of all cancers.
Type 2 diabetes: Chronic inflammation contributes to insulin resistance—a hallmark of type 2 diabetes. Persistent inflammation disrupts normal insulin signaling, resulting in elevated blood sugar levels and the development of diabetes.
Rheumatoid arthritis (RA): RA is an autoimmune disease in which the immune system mistakenly attacks the body’s healthy joint tissues. Research shows rheumatoid arthritis develops years after systemic (widespread) inflammation begins.
Asthma: Exposure to allergens (e.g., pollen, pet dander) and environmental irritants (e.g., air pollution, cigarette smoke) can initiate an immune response and chronic inflammation in the airways, leading to asthma.
Obesity: A diet high in processed foods, sugar, and saturated fats can trigger chronic low-grade inflammation and contribute to weight gain.
Endometriosis/Adenomyosis: Chronic inflammation in the uterus or pelvic area can cause endometrial tissue to grow outside of the uterus (endometriosis) or within the uterine muscle (adenomyosis), causing pelvic pain, severe menstrual cramps, and heavy menstrual bleeding.
Depression: Researchers exploring the link between depression and inflammation discovered that chronic inflammation plays a role in the development of depression in some people.
ActiPatch sold in the UK on Boots' shelves with a social media campaign costing under $50k
<<<<<<<< They brought this junk to market and it doesn't sell >>>>>>>>
2015 sales - $2.339 million
2016 sales - $2.016 million
2017 sales - $1.763 million
Ran across a Phantom Limb article today, even people in the 16th century acknowledged Phantom Limb Pain
Phantom limb pain: Why does my amputated leg still hurt?
Story by Selma Narine, Deutsche Welle
Amputees often feel a phantom pain where the lost limb used to be. The brain is confused. But mirror therapy can help — perhaps better than pain killers.The question "Where does it hurt?" is not easy to answer for Thomas Frey -- his aching leg no longer exists.
Frey lost his leg in a serious accident more than 30 years ago. But almost immediately after he lost it, he felt a severe pain -- right there, where his leg used to be.
It's what's known as phantom limb pain, or simply phantom pain. And it's quite common: Over 70% of amputees experience phantom pain.
People can get phantom pain after losing arms and legs, and other body parts, including breasts after a mastectomy, as well as teeth.
Frey said it was like a migraine: "Impulses that last a few seconds. Then it's quiet again for five minutes. It can go on for hours."
The pain is unbearable, said Frey, and restricts him in his everyday life. "[When I have] phantom pain, I can't meet friends for dinner, I can't go to meetings," he said.
There are references to "phantom pain" in the medical literature as far back as the 16th century, but researchers are still trying to explain the phenomenon.
Thomas Weiss, a physiologist, who has studied phantom pain intensively, said the current thinking is that "an amputation changes the entire nervous system."
In other words, nerve pathways change in the residual limb, and also in the spinal cord and brain.
Read the full article here, https://www.msn.com/en-us/health/other/phantom-limb-pain-why-does-my-amputated-leg-still-hurt/ar-BB1jXjbN?ocid=msedgntp&pc=ASTS&cvid=ccf5ae71d0374506884973604667df1e&ei=89
Set the Record Straight Then
<<<<<<<<<< NOT mocking at all >>>>>>>>>>>
State that you accept as a fact Amputee Patients can feel pain in an arm or leg that has been amputated.
The University of California, San Diego researcher Dr. Brian Ilfeld found, in a published case report, that 66% of the clinical study patients had reduced pain from using the RecoveryRx device.
"50% to 85% of people with an amputation develop persistent pain, which has a significant negative impact on physical and mental health and substantially decreases overall quality of life. Postamputation pain rarely spontaneously resolves and is frequently resistant to available treatments [1]." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394547/
Still mocking Amputee patients, many of which lost their limbs in US Military Service
What kind of a person does that.
Actually one needs to look at a 10 year chart to understand BIEL
It shows that BIEL is a News Driven stock.
There may be a minor uptick before the news is made public, as word starts leaking, but major SP gains always have positive news.
February 2014, 4th Generation ActiPatch, 4.4 billion shares Traded in February, SP .0002 - .0084
October 2015, BIEL is reclassified to a Class 2 Medical Device, 3.8 billion shares Traded in October, SP .0004 - .0025
February 2017, FDA Clears ActiPatch for Foot and Knee use OTC, 7.16 billion shares Traded in February, SP .0002 - .003
January 2021, KT Tape Wave OEM Deal, 2.3 billion shares Traded in January, SP .0011 - .004
February 2021, Q4 2020 Revenue/CE Mark, 3.45 billion shares traded in February, SP .003 - .008
I have grown tired of explaining things to LCA (Low Comprehension Art)
Find a 7 year old in your neighborhood and have them fill you in.
LMFAO, forgot to mention a $25 Sell 2 minutes before the Close dropped the SP to .0001, the rest of the day was all Buying
<<<<<<<<<< And did you see what this closed at today? >>>>>>>>>>>
Buys = 5,041,000 shares
Sells = 279,214 shares
You know the 'Usual Suspects' are getting desperate when they try to spin a day like yesterday as a good day for bashers.
Been hanging around Art too much, there is no market for "unloading their billions of shares" until BIEL becomes solvent.
Management knows this. A successful BIEL is the only way they get their Convertible Loans repaid. That fact is an effective motivator.
Another day with Buys vastly outnumbering Sells, 95% Buys
Buys = 5,041,000 shares
Sells = 279,214 shares
https://ih.advfn.com/stock-market/USOTC/bioelectronics-pk-BIEL/trades
Nahhhh, the perfect example of "totally worthless" is someone making 28,250 posts on a stock message board, many of them fraudulent, over the last 14 years trying to destroy a company and failing every year.
In addition to the 2023 financials BIEL has communicated with shareholders 3 times this year, one COB Update on 2/15/2024 and two PRs, 2/23/2024 and 3/25/2024.
As you well know BIEL has moved to the annual only financial report to save the expense of Quarterly reporting.
Here are the 3 communications since you appear to have forgotten about them:
FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.
The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans. As I have mentioned many times, I believe our strategic mission is to focus and succeed on three major fronts, these being research, manufacturing processes, and sales. Today, I will focus on the first of these, although I will briefly mention the two other vital components of our mission.
CLINICAL TRIALS IN PROGRESS
We have two investigator sponsored clinical trials now in the field. The first is a surgical analgesia trial being conducted at the University of San Diego. This is a major double-blind, randomized assignment study, involving 120 post-surgical patients who have undergone one of eleven different types of surgery often associated with at least moderate pain. Examples are knee and hip arthroplasty, non-mastectomy breast surgery and hernia repair. These patients are being studied for 180 days, with the primary outcome measures being pain levels and opioid consumption measured on postoperative days 1,2,3 and 7 with follow up measures taken on days 14, 21, 28 and 180 days. These latter measures are important since acute surgical pain can turn into chronic pain. Thus, the study will be able to assess the efficacy of our model 088 in not only reducing the acute surgical pain and opioid use, but also reducing or even eliminating any chronic pain resulting from surgery. Such findings will be new to the literature and should provide important evidence on reducing opioid use and minimizing post-surgical chronic pain.
The last of the 120 patients was enrolled in October of 2023 and the anticipated end date for this 180-day study is now expected to be March 20, 2024. For more information: https://clinicaltrials.gov/study/NCT05399355
The second study is being conducted at Stanford University Medical Center and is focused on thumb arthritics using a modified version of our 088 model device designed especially for the use around the thumb joint. This double-blind, randomized controlled study will involve 60 subjects who are suffering from arthritic pain in the thumb area of the hand. Like the UCSD study, this four-week study is nearing completion. Interim results on 40 patients have already been analyzed and at least 53 patients have been enrolled. The primary measure for this study is the reduction of pain after 4 weeks. The researchers tell us that they are looking at an April-May time frame to finish the study. Assuming continued favorable results, this study should provide access to a new market for the Company. For more information: https://clinicaltrials.gov/study/NCT05315297
COMPLETED STUDIES NOW UNDER PEER REVIEW
There are two randomized controlled studies that have been completed. The first was an investigator sponsored study to treat chronic post-amputation pain with our nonthermal, pulsed shortwave (radiofrequency) therapy using our model 088 device. This study used a cross-over design where the subject got both the active and sham device for 4 weeks and after each of these four-week periods the subjects record the change in average residual and phantom limb pain. This study is complete and the results are now in press and will appear in the Regional Anesthesia and Pain Medicine journal. The abstract will be presented at the American Society of Regional Anesthesia conference in March. Pending publication, we intend to pursue marketing into this pain market given its size (over 1.5 million people have lost a limb). Importantly, up until now there is no effective way of treating phantom limb pain.
The second completed double-blind randomized controlled study looked at increasing the quality of life of canines suffering from symptoms of osteoarthritis. This clinical trial studied 60 canines and found significant improvements in a) behavioral measures often associated with pain and b) range of motion in the affected limbs. In fact, 96% of the treated dogs showed significant improvements in one or both of these measures compared to 4% for the dogs that got the placebo device. The paper documenting these results is currently under third round peer review at the Veterinary Medicine and Science journal. The authors anticipate hearing back within a month as the last request for changes indicated the need for only minor revisions. Based on these positive results, the Company has already designed and ordered new veterinary packaging and plans to commence selling into the veterinary market.
MANUFACTURING
The Company, working with its Chinese manufacturer, recently redesigned the manufacturing process to increase the reliability and shelf life of its current OTC product. The Company also did a proof-of-concept production run of its newly designed RecoveryRx product that is 50% more powerful and has a larger antenna thereby increasing the size of the surgical incision that can be treated. The plan is to test market these devices in the near future.
SALES
Company representatives attended the Modern Musculoskeletal Care Symposium this past weekend in Columbus, Ohio. We were once again invited to exhibit and Dr. Berend spoke to the medical professionals in attendance about “Non Thermal Pulsed Shortwave Therapy for Pre and Post Op Pain” Our attendance at the show was predicated on the expectation that the use of RecoveryRx will expand through the OrthoAlliance (https://orthoalliance.com/) organization in the next few months.
The Company is continuing talks with major distributors, both internationally and domestically. These talks are in different stages of progress, from discussing final approval and registration, to initial exploration of possible interest. Given the unique advantages of our product offerings, these discussions often take a long time, especially with major distributors that have multiple levels of management review.
POSSIBLE LEGAL ACTION
The Company is exploring entering into legal action against Mundi Pharma South East Asia for breach of contract. They signed a five-year contract in October of 2018 with BioElectronics Corporation, agreeing to purchase a minimum of approximately $14,000,000 worth of product from us over the next five years of the contract. However, they never completed the registration of the products into the five territories that we granted them exclusive distributorship and only took ownership of a small amount of the inventory. We have engaged both local counsel and counsel in Singapore, where any arbitration action would need to take place. The Company is actively seeking financial backing to support this legal action.
SUMMARY
I am happy to report that the Company is still making progress, especially in terms of research. However, we still have a long way to go in terms of generating significant sales. Thus, it is important that we continue to look for strong partners who can take our innovative product into the marketplace and generate the sales that we need to become the vibrant company that we aspire to be, one that is not only profitable, but also provides products that significantly relieve both acute and chronic pain.
Finally, I want to thank our shareholders who have shown support for us over these years. We acknowledge that our progress has been slow at times and that we have yet to deliver the hoped-for home run in terms of profit, but I can guarantee you that the Company remains committed to staying the course and turning our expertise in pulsed shortwave therapy into a profitable company.
Richard Staelin, PhD
************************************************************************************************************
Beneficial Treatment Effect for Phantom and Residual Limb Pain Identified
FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device.
"Treating intractable postamputation pain with wearable, non-invasive, non-thermal, pulsed shortwave (radiofrequency) therapy: a randomized, double-masked, sham-controlled, crossover pilot study" is now published at: https://rapm.bmj.com/content/early/2024/02/21/rapm-2023-105154 The study was investigator sponsored and funded by the University of California San Diego Department of Anesthesiology.
The study design had patients first wear BioElectronics’ Model 088 device (about ½ wore the sham device and the remaining wore the active device) on the residual part of the limb for 28 days. After 28 days, the patient began wearing the opposite device, i.e., the sham group wore the active device, and the treatment group wore the sham device, again for 28 days. Three major measures were obtained for both phantom pain and residual pain along with a global assessment of change in both phantom and residual pain before, during, and after each 28 days.
The researchers presented their findings in a series of graphs over time depending on whether the patient was wearing the sham or active device. When wearing the sham device, patients reported, on average, no change in the median phantom limb pain or pain in the residual limb. They also reported no median change in their global assessment of pain. In contrast, when the patients were wearing the active device, they reported, on average, a 40% to 50% decrease in the median measures for both average and worst residual and phantom limb pain by day 7 and this reduction continued through day 28. Moreover, a majority of patients, when wearing the active device, reported the highest level of global change in residual pain, i.e., “very much better” by day 21 and this continued through day 28. This measure on the phantom limb pain was also positive, with the majority of subjects reporting being “much better”.
The researchers conclude that further study is warranted given that an identified beneficial treatment effect is associated with using BioElectronics’ Model 088 in the setting of a low-cost and low-risk intervention.
Currently, there are 1.6 million people in the United States who are living with the loss of a limb. Due to the rising number of people who have diabetes, a major cause of amputations, it is estimated that the number of amputations could grow to as many as 3.6 million by 2050. More than 7 in 10 people who have had an arm or leg amputated have pain in the lost limb, which they perceive as still present. Nearly 4 in 10 have severe pain, and many also report depression and anxiety linked with phantom limb pain making it hard to sleep, work, and take part in family and social activities. People who have phantom limb pain are often prescribed medications, including opioids, but opioid medications are effective in only about half of these patients and can also have serious side effects, including the risk of addiction.
Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.
******************************************************************************************************
BioElectronics Corporation Announces the Publication of a Canine Arthritis Study
FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. The study was published online by Veterinary Medicine & Science, and can be viewed here: https://doi.org/10.1002/vms3.1408
A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog’s quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics’ Model 088 device was secured near the cervical region of the dog’s spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily.
Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Ninety-six percent of the treatment group showed either increased PROM or improved behavioral changes or both compared to 4% for the placebo group. Most changes occurred within the first 8 days of treatment.
Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other strenuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. Dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such as aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA.
Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.
Given your cognitive issues lets simplify it for you
Below is the ihub Trades data for 5/13/2024, the Facts. "Buy Volume 6,712,222", "Sell Volume 2,027,345", "? Vol." (Neutral) 9,626,666 .
Over 3x more Buys @ 2 than Sells @1 today, period.
<<<<<<< while 2,020,345 traded at .0002. >>>>>>>> This is 100% WRONG!!!
<<<<<<< 16,338,888 traded at that .0001 and .00015 >>>>>>> This is 100% WRONG!!!
Leaving two options, Liar or Cognitively Impaired.
Typical Useless Analysis from Low Comprehension Art
<<<<<<<< .0001 and .00015 printed 15 times out of 23 trades >>>>>>>>>>
You can't lump the Sells at .0001 with the Neutral Trades at .00015. There is a reason ihub separates Trades into 3 categories, Buys, Sells, ? (Neutral). Retail investors can not enter an order for .00015. If these were Retail orders they were entered as a Buy at .0002 and a MM stepped in and filled them at .00015. I have had this happen on numerous Buy orders.
Sells were 2.027 million shares and that is it, period.
Neutral Trades at .00015 were 9.626 million shares, period.
<<<<<<< while 2,020,345 traded at .0002. >>>>>>>> This is 100% WRONG!!!
<<<<<<< 16,338,888 traded at that .0001 and .00015 >>>>>>> This is 100% WRONG!!!
Buys at .0002 were 6.712 million shares, Over 3x more Buys than Sells today.
MMs Shorted over 13 million shares today per FINRA.
Date .... Symbol .. Short vol ... Total vol
20240513 | BIEL| 13868888 | 18366233
Send him a PM
seven-up
Re: Hawk05 post# 318119
Thursday, July 20, 2023 1:55:15 PM
Post# 318508 of 329220
Posting simple posts is easier for people to understand LMAO
Talk to seven-up he has mentioned ActiPatch for prostate issues many times
How could anyone forget the SEC Illegal Judge Fiasco
<<<<<<<< Oh how quickly they forget about that SEC investigation >>>>>>>>
The SEC that knowingly used illegal Judges, that they could hire and fire at will, to achieve a 90% conviction rate.
SEC continued using those unlawful Judges until the Supreme Court told them to stop it, reversing hundreds of SEC Administrative Proceedings decisions including BIEL's.
It looks like KW/IBEX were reinvesting almost all of the proceeds from the sale of converted shares to fund BIEL. In one period mentioned, 1/2010 - 2/2015, IBEX took in $4 million and reinvested $5 million. Due to other sources of financing being unavailable the IBEX loans and reinvestments were essential in keeping the lights on at BIEL.
"Kelly Whelan founded IBEX sometime before 2005 with money raised by taking funds from her personal savings and other sources, with the intention of investing in her father's company, BioElectronics." (page 5)
"Overall, from January 2010 through February 9, 2015, IBEX received approximately $4 million from the Liquidating Entities and sent approximately $5 million to BIEL." (page 7)
It doesn't take a PHD to understand that BIEL will Trade in the low trips until an announcement of significant, revenue producing news
That significant positive event may be in process or may have already occurred but, as we have seen in the past, the PR announcements of events involving partners are controlled by BIEL's partners.
Three Options:
1) Become frustrated waiting on news and Sell
2) Wait for another XX number of days for a positive event knowing BIEL's management loses millions of $$$ if they don't turn the company around, most skin in the game
3) Take out your frustrations with negative posts about BIEL every day on a message board
The number of shares needed to satisfy loan repayment fluctuates with the BIEL Share Price
Loan repayment at a .002 SP takes one tenth the number of shares compared to a .0002 SP.
Sales-Track only shows only one thing
The poster who fraudulently represents Sales-Track as a real company is knowingly presenting false information on the BIEL Board in an effort to damage the company. It is important to remember this deception when reading anything ddls posts.
Twice as many Buys as Sells Today, ----- just sayin
ActiPatch is the Retail product, RecoveryRx is the Medical Professional product having a higher price
That unhinged post speaks volumes about the mental state of the current batch of 'Usual Suspects'
Yeah, it's a real bitch when someone ruins your scam by telling the whole story
More Misleading Information from the Board's Biggest Bozo
<<<<<<< failed to show anything in the FDA Opioid Challenge >>>>>>>
The FDA Opioid Challenge was entered by over 250 companies and there were just 8 companies selected. I will do the math for you, over 242 companies entered and were not selected, some entrants had large company resources like Pfizer who spent $7 billion on R&D in 2018 and was not selected.
Good Grief, Mundiparma's parent company Purdue was shut down
<<<<<<<<<<<<< long list of this company's failures >>>>>>>>>>>>>>>
By all means, BIEL should have foreseen the 2021 BK of Purdue and not signed the 2018 deal with Mundipharma.
Purdue Pharma Is Dissolved and Sacklers Pay $4.5 Billion to Settle Opioid Claims
"The ruling in bankruptcy court caps a long legal battle over the fate of a company accused of fueling the opioid epidemic and the family that owns it."
New York Times Published Sept. 1, 2021 Updated Sept. 17, 2021
"Purdue Pharma, the maker of the highly addictive painkiller OxyContin, was dissolved on Wednesday in a wide-ranging bankruptcy settlement that will require the company’s owners, members of the Sackler family, to turn over billions of dollars of their fortune to address the deadly opioid epidemic."
"Judge Robert Drain of the U.S. Bankruptcy Court in White Plains, N.Y., approved the settlement, saying he wanted modest adjustments. The painstakingly negotiated plan will end thousands of lawsuits brought by state and local governments, tribes, hospitals and individuals to address a public health crisis that led to the deaths of more than 500,000 people nationwide."
The MundiPharma Deal was Real, once again suffering from a selective memory
<<<<<<<<<<<<< was MundiPharma real >>>>>>>>>>>>>>>>
Mundipharma had a 'actipatch.au' website and had recruited several Australian pharmacy chains to carry ActiPatch. Mundipharma was part of the Sackler/Purdue empire which was hit with billions of dollars in opioid lawsuits in 2021.
JULY 23, 2018 NEWS, PRESS RELEASES 0 COMMENTS IANWAR@BIELCORP.COM
FREDERICK, MD, July 23, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that Mundipharma Pty Limited (Mundipharma), https://www.mundipharma.com.au/ has added ActiPatch® to its pain management portfolio, by acquiring the exclusive Australian and New Zealand distribution rights to the ActiPatch® Musculoskeletal Pain Therapy medical device.
“The addition of ActiPatch® to our existing pain medications confirms our commitment to help clinicians manage pain with a multimodal approach, including non-drug therapies. Our education programs for healthcare professionals emphasize the importance of stepped multimodal pain management, so I’m delighted that we’re now able to offer ActiPatch®,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand.
Thanks toohot, The picture on your link looks like it could be the newly redesigned ActiPatch
Notice there are no chips or electrical connections visible through a clear resin, the entire face is now white and the green light has been moved.
2/15/2024 Update
"The Company, working with its Chinese manufacturer, recently redesigned the manufacturing process to increase the reliability and shelf life of its current OTC product."
With BIEL conserving resources in most all areas in 2023 would they spend $272k on R&D, including the redesign of ActiPatch, if they did not feel it was needed to close a deal?
Definitely been hanging with Art if you won't admit the significant difference between a 5% success rate versus a 25% success rate.
You are casting too wide of a net, when specifying 'Medical Device Companies' the failure rate is 75%
<<<<<<<< 19 of 20 biotechs fail. >>>>>>>>
"In the US, 75% of medical device start-ups fail, and 98% of digital health startups fail. Moreover, 75% of venture-backed companies never return cash to their investors, and in 30-40% of cases, investors lose their entire initial investment. Oct 25, 2023
When looking at failure rates of all Startup businesses combined the rate is 90%.
"The average cost to bring a 510(k) product from concept to market exceeds $31 million, with greater than 77% of the cost—approximately $24 million— spent on regulatory and FDA-related activities. The cost of a PMA averages $94 million, with $75 million spent on FDA-linked stages. That is nearly 80% of the total amount."
BIEL does not have just 1 FDA 510k Indication but 5 :
Blepharoplasty (eyelid surgery) K022404
Postoperative Pain K190251
Plantar Fasciitis K152432 (OTC)
Knee Osteoarthritis K152432 (OTC)
Musculoskeletal Pain K192234 (OTC)